All In MedTech

FDA Clearance Tracker · P900030

CONTIGEN (TM) BARD (R) COLLAGEN IMPLANT

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Sep 30, 1993 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product code

Decided

Sep 30, 1993

Approval withdrawn

Time to decision

1,252 days

Received Apr 27, 1990. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P900030
Device name
CONTIGEN (TM) BARD (R) COLLAGEN IMPLANT
Applicant location
Goleta, CA
Received
Apr 27, 1990
Decided
Sep 30, 1993
Decision
Approval withdrawn
Supplements
9 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code LNM

FDA's approval statement

As written in FDA's record.

Approval for the Contigen™ Bard® Collagen Implant. This device is indicated for use in the treatment of urinary incontinence due to intrinsic sphincter deficiency (poor or non-functioning bladder outlet mechanism) that may be helped by a locally injected bulking agent. Contigen implant therapy is intended only for patients who have shown no improvement in their incontinence for at least 12 months.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code LNM (AGENT, BULKING, INJECTABLE FOR GASTRO-UROLOGY USE).
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Allergan, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.